The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

Her previous roles at Juno Therapeutics, Celgene, and Lyell Immunopharma, and her current position as head of research at Tune Therapeutics, underscore her commitment to pioneering cancer treatments.

She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...

Her previous roles at Juno Therapeutics, Celgene, and Lyell Immunopharma, and her current position as head of research at Tune Therapeutics, underscore her commitment to pioneering cancer treatments.

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...